Metastasis is the main cause of death from cancer. Fortunately, metastasis is an inef fi cient process. Only a few of the many cancer cells detached from the primary tumor succeed in forming secondary tumors. Metastatic inef fi ci ency varies depending on the location within an organ, but the malignancy may continue to grow preferentially in a speci fi c tissue environment. Some of the cancer cells shed from the primary tumor are lost in the circulation due to hemodynamic forces or the immune system, macrophages, and natural killer cells.
Periodic rejection of a drug by FDA, which was previously approved by the FDA, is not uncommon. Most recently, the FDA ruled that Avastin should not be used to treat advanced breast cancer, although it remains on the market to treat other cancers, including colon and lung malignancies. Side-effects of Avastin include high blood pressure, massive bleeding, heart attack, and damage to the stomach and intestines.
Unwanted side effects of some drug excipients (e.g., propylene glycol, menthol) may also pose safety concerns in some patients. Excipients are de fi ned as the constituents of the pharmaceutical formulation used to guarantee stability, and physicochemical, organoleptic and biopharmaceutical properties. Excipients frequently make up the majority of the volume of oral and parenteral drugs. Not all excipients are inert from the biological point of view. Although adverse drug reactions caused by the excipients are a minority of all adverse effects of medicinal products, the lack of awareness of the possible risk from excipients should be a concern for regulatory agencies, physicians, and patients (Ursino et al. 2011) . Knowledge of the potential side effects of excipients is important in clinical practice.
It is known that chemotherapy can cause very serious side-effects. One most recent example of such side-effects was reported by Rubsam et al. (2011) . Advanced hepatocellular carcinoma (HCC) induced by hepatitis C virus was treated with Sorafenib. It is an oral multikinase inhibitor that interferes with the serine/threonine kinases RAF-1 and B-Raf and the receptor tyrosine kinases of the vascular endothelial growth factor receptors and the platelet-derived growth factor receptor-beta. Although sorafenib is effective in regressing HCC, it shows serious side-effects including increasingly pruritic and painful skin changes (cutaneous eruption).
An example of unnecessary surgery is the removal of all the armpit lymph nodes after a biopsy when a sentinel node shows early stage breast cancer; removal of only the sentinel node may be needed. Limiting the surgery to the sentinel node avoids painful surgery of the armpit lymph nodes, which can have complications such as swelling and infection (such limited surgery is already being practiced at the Memorial Sloan-Kettering Cancer Research Center). Radiation-induced second cerebral tumors constitute a signi fi cant risk for persons undergoing radiotherapy for the management of cerebral neoplasms. High-grade gliomas are the most common radiation-induced tumors in children (Pettorini et al. 2008) . The actual incidence of this complication is not known, although it is thought to be generally low.
Medical Radiation
Chromosome aberrations induced by ionizing radiation are well-known. Medical radiation-induced tumors are well-documented. For example, several types of tumors (sarcomas, meningiomas) can develop in the CNS after irradiation of the head and neck region (Parent 1990) . Tumorigenic mechanisms underlying the radiation therapy of the CNS are discussed by Amirjamshidi and Abbassioun (2000) (see below).
Radiation therapy is commonly used to treat, for example, patients with primary and secondary brain tumors. Unfortunately, ionizing radiation has limited tissue speci fi city, and tends to damage both neoplastic and normal brain tissues. Radiation-induced brain injury, in fact, is a potential, insidious later cerebral side-effect of radiotherapy. Most commonly it consists of damage in small arteries and capillaries, resulting in secondary processes of ischemia.
After radiation therapy, imaging techniques (CT, MRI, SPECT) can be used to assess treatment response and detect radiation-induced lesions and recurrent tumors. Optical spectroscopy has also been used for detecting radiation damage (Lin et al. 2005) . The F 500 nm spectral peak allows accurate selection of tissues for biopsy in evaluating patients with new, contrast enhancing lesions in the setting of previous irradiation. This peak is highly correlated with a histological pattern of radiation injury. Deep lesions require a stereotactic biopsy to be conclusive. Also, much of the radiation effect is mediated by acute and chronic in fl ammatory cellular reactions. Biopsy samples supplement pathological differentiation of radiation effect from tumor progression. It should be noted that most of the biopsies show radionecrosis as well as scattered tumor cells.
Women treated with therapeutic chest radiation may develop cancer. This possibility becomes exceedingly serious considering that 50,000-55,000 women in the United States have been treated with moderate to high-dose chest radiation (~20 Gy). This possibility is much more serious for pediatric or young adult cancer patients, because these women are at a signi fi cantly increased risk of breast cancer and breast cancer mortality following cure of their primary malignancy (Mertens et al. 2008) . A recent study also indicates that such young women develop breast cancer at a young age, which does not appear to plateau (Henderson et al. 2010) . In this high-risk population, ironically there is a bene fi t associated with early detection. In other words, young women with early stage breast cancer following chest radiation have a high likelihood for favorable outcome, although life-long surveillance is needed.
Presently, although approximately 80% of the children with cancer are cured, the curative therapy could damage a child's developing organ system; for example, cognitive de fi cits following cranial radiotherapy are well known. Childhood survivors of malignant diseases are also at an increased risk of primary thyroid cancer (Sigurdson et al. 2005) . The risk of this cancer increases with radiation doses up to 20-29 Gy. In fact, exposure to radiation therapy is the most important risk factor for the development of a new CNS tumor in survivors of childhood cancer, including leukemia and brain tumors. The higher risk of subsequent glioma in children subjected to medical radiation at a very young age re fl ects greater susceptibility of the developing brain to radiation. The details of the dose-response relationships, the expression of excess risk over time, and the modifying effects of other host and treatment factors have not been well de fi ned (Neglia et al. 2006) .
A recent study indicates that childhood brain tumor survivors are at an increased risk of late endocrine effects, particularly the patients treated with cranial radiation and diagnosed at a younger age (Shalitin et al. 2011) . Among children with cancer, the application of radiotherapy, therefore, should not be taken lightly, and it should be administered only when absolutely necessary to successfully treat the primary tumor. When radiotherapy is administered, use of the minimum effective dose tends to minimize the risk of second CNS neoplasms (late effect). Prolonged follow-up of childhood cancer survivors (particularly those treated with radiation) is necessary because of the long period between treatment and the development of malignancy. This practice should be a part of the effective therapy of the primary disease.
It is well established that radiation doses are related to risk for subsequent malignant neoplasms in children with Hodgkin's disease. It has been reported that increasing radiation dose was associated with increasing standardized incidence ratio (p = 0.0085) in survivors of childhood Hodgkin's disease (Constine et al. 2008) . Approximately, 75% of subsequent malignancies occurred within the radiation fi eld. Although subsequent malignancies occur, for example, in breast cancer survivors in the absence of radiotherapy, the rise increases with radiation dose.
The pertinent question is: Is it always necessary to practice tumor surgery, radiotherapy, chemotherapy or hormonal therapy or a combination of these therapies? Although the conventional belief is that cancer represents an "arrow that advances unidirectionally", it is becoming clear that for cancer to progress, it requires cooperative microenvironment (niche), including immune system and hormone levels. However, it is emphasized that advanced (malignant) cancers do not show regression, and require therapy. In the light of the inadequacy of standard treatments of malignancy, clinical applications of the stem cell technology need to be expedited.
Prostate Cancer
There were an estimated 217,730 new cases of prostate cancer in the United States in 2010 with 32,050 deaths, making it the second leading cause of cancer deaths in men. Currently, there are more than 2,000,000 men in the United States who have had radical or partial prostate surgery performed. Considering this huge number of prostate surgeries and the absence of a cumulative outcome data, it seems appropriate to carefully examine the bene fi ts of radical surgery, especially in younger men.
Clinical prostate cancer is very rare in men of the ages younger than 40 years. In this age group the frequency of prostate malignancy is 1 in 10,000 individuals. Unfortunately, the incidence of malignancy increases over the ensuing decades, that is, the chance of prostate malignancy may reach to 1 in 7 in men between the ages of 60 and 79 years. Reactive or aging-related alterations in the tumor microenvironment provide suf fi cient in fl uence, promoting tumor cell invasion and metastasis. It has been shown that nontumorigenic prostate epithelial cells can become tumorigenic when cocultured with fi broblasts obtained from regions near tumors (Olumi et al. 1999) .
Prostate cancer treatment is one of the worst examples of overtreatment. Serum prostate speci fi c antigen (PSA) testing for the early detection of prostate cancer is in wide use. However, the bene fi t of this testing has become controversial. The normal cut-off for serum levels of PSA is 4 ng/ml, so a man presenting with a PSA above this level is likely to require a rectal biopsy, but only 25% of men with serum levels of PSA between 4 ng and 10 ng/ml have cancer (Masters 2007) . The PSA threshold currently being used for biopsy ranges between 2.5 and 3.4 ng/ml. Up to 50% of men presenting with prostate cancer have PSA levels within the normal range. It is apparent that screening of prostate cancer using PSA has a low speci fi city, resulting in many unnecessary biopsies, particularly for gray zone values (4 ng-10 ng/ ml). According to one point of view, the risks of prostate cancer overdetection are substantial. In this context, overdetection means treating a cancer that otherwise would not progress to clinically signi fi cant disease during the lifetime of the individual. Overdetection results in overtreatment. The advantages and limitations of PSA test in diagnosing prostate cancer were reviewed by Hayat (2005 Hayat ( , 2008 .
Androgen deprivation therapy (ADT) is an important treatment for patients with advanced stage prostate cancer. This therapy is carried out by blocking androgen receptor or medical or surgical castration. Although ADT is initially very effective, treated tumors inevitably progress to androgen-independent prostate cancer (AIPC), which is incurable. One possible mechanism responsible for the development of AIPC is modulation of the tissue microenvironment by neuroendocrine-like cancer cells, which emerge after ADT (Nelson et al. 2007) .
Recently, Pernicova et al. (2011) have further clari fi ed the role of androgen deprivation in promoting the clonal expansion of androgen-independent prostate cancer. They reported a novel linkage between the inhibition of the androgen receptor activity, down-regulation of S-phase kinase-associated protein 2, and the formation of secretory, senescent cells in prostate tumor cells. It is known that several components of the SASP secretome, such as IL-6, IL-8, KGH, and epidermal growth factor, are capable of transactivating androgen receptor under androgen-depleted conditions (Seaton et al. 2008) . It needs to be pointed out that androgen deprivation therapy, used in high-risk patients with prostate cancer, may cause reduced libido, erectile dysfunction, fatigue, and muscle loss; osteoporosis is also a late complication. Therefore, periodic bone density scanning needs to be considered.
Recently, the FDA cleared the use of NADiA (nucleic acid detection immunoassay) ProsVue prognostic cancer test. This proprietary nucleic acid detection immunoassay technology identi fi es extremely low concentrations of proteins that have not been routinely used as a diagnostic or prognostic aid. It is an in vitro diagnostic assay for determining the rate of change of serum total PSA over a period of time. The assay can quantitate PSA at levels <1 ng/ml. This technique can be used as a prognostic marker, in conjunction with clinical evaluation, to help identify patients at reduced risk for recurrence of prostate cancer for years following prostatectomy. It targets the early detection of proteins associated with cancer and infectious diseases. This technique combines immunoassay and real-time PCR methodologies with the potential to detect proteins with femtogram/ml sensitivity (10-15 g/ml). Additional clinical information is needed regarding its usefulness in predicting the recurrence.
A signi fi cant decrease in the risk of prostate cancer-speci fi c mortality is observed in men with few or no comorbidities. Indeed, active surveillance in lieu of immediate treatment (surgery or radiation, or both) is gaining acceptance. Most men with prostate cancer, even those with high-risk disease, ultimately die as a result of other causes (Lu-Yao et al. 2009 ). Debate on this controversy is welcome, but narrow opinions and facile guidelines will not lead to facts and new information; men worldwide deserve it (Carroll et al. 2011) . Automatic linking positive diagnosis with treatment, unfortunately, is a common clinical practice. Unfortunately, even men who are excellent candidates for active surveillance in the United States often undergo some treatment. Deferment of treatment is advised in men with low-risk disease, especially of a younger age.
Active surveillance is proposed for patients with low-risk prostate cancer in order to reduce the undesirable effects of overdiagnosis. Prostate speci fi c antigen serum level lower than 10 ng/L and Gleason score lower than 7 are the main criteria to select patients for active surveillance. The correct use of these two criteria is essential to differentiate between aggressive and nonaggressive prostate cancer. Autopsy studies indicate that approximately one out of three men older than 50 years show histological evidence of prostate cancer (Klotz, 2008) . Thus, a large proportion of prostate cancers are latent, never destined to progress, or affect the life of the patient. It is estimated that the percentage of low-risk prostate cancer is between 50 and 60% of newly diagnosed cases. A large number of patients die having prostate cancer, but not because of this cancer (Filella et al. 2011) .
First whole genome sequences of prostate tumors were recently published online in Nature journal (vol. 470: 214-220, 2011) . This study revealed that rather than single spelling errors, the tumor has long "paragraphs" of DNA that seem to have broken off and moved to another part of the genome (rearrangement of genes), where they are most active. These portions of DNA contain genes that help drive cancer progression. The mutated genes involved include PTEN , CADM2 , MAG12 , SPOP, and SPTA1 . This information may lead to the development of more ef fi cient, less invasive ways to diagnose and treat this cancer. Such information, in addition, should lead to personalized therapeutics according to sequencing results of different gene mutations or chromosomal rearrangements. The urgent need of such studies becomes apparent considering the huge number of new cases of prostate problems reported every year.
In contrast to prostate cancer, cardiovascular disorders take the heavier toll of life. In other words, the risk of death for men in the United States between the ages of 55 and 74 years due to cardiovascular disease surpasses that of prostate cancer. Cardiovascular disease is the most common of the chronic non-communicable diseases that impact global mortality. Approximately, 30% of all deaths worldwide and 10% of all healthy life lost to disease are accounted for by cardiovascular disease alone.
In conclusion, initial treatment with standard surgery, irradiation, chemotherapy, or hormonal therapy, or combination of these protocols can result in both local and systemic sequelae. Therefore, surveillance for late recurrence and secondary primary malignancies is recommended for most cancer patients. Patients with breast, lung, prostate, colorectal, and head and neck cancers constitute the largest groups requiring long-term monitoring and follow-up care. It is recognized that scienti fi c journals and books not only provide current information but also facilitate exchange of information, resulting in rapid progress in the medical fi eld. In this endeavor, the main role of scienti fi c books is to present current information in more details after careful additional evaluation of the investigational results, especially those of new or relatively new therapeutic methods and their potential toxic side-effects. Although subjects of diagnosis, drug development, therapy and its assessment, and prognosis of tumors of the central nervous system, cancer recurrence, and resistance to chemotherapy are scattered in a vast number of journals and books, there is need of combining these subjects in single volumes. An attempt will be made to accomplish this goal in the projected ten-volume series of handbooks.
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In the era of cost-effectiveness, my opinion may be minority perspective, but it needs to be recognized that the potential for false-positive or falsenegative interpretation on the basis of a single laboratory test in clinical pathology does exist. Interobserver or intraobserver variability in the interpretation of results in pathology is not uncommon. Interpretative differences often are related to the relative importance of the criteria being used.
Generally, no test always performs perfectly. Although there is no perfect remedy to this problem, standardized classi fi cations with written de fi nitions and guidelines will help. Standardization of methods to achieve objectivity is imperative in this effort. The validity of a test should be based on the careful, objective interpretation of the tomographic images, photo-micrographs, and other tests. The interpretation of the results should be explicit rather than implicit. To achieve accurate diagnosis and correct prognosis, the use of molecular criteria and targeted medicine is important. Equally important are the translation of molecular genetics into clinical practice and evidence-based therapy. Translation of medicine from the laboratory to clinical application needs to be carefully expedited. Indeed, molecular medicine has arrived. This is the ninth volume in the series, Tumors of the Central Nervous System . As in the case of the seven previously published volumes, this volume mainly contains information on the diagnosis, therapy, and prognosis of brain tumors. Various aspects of nine types of brain tumors (Astrocytoma, Lymphoma, Supratentorial Tumors, Glioneuronal Tumors, Gangliogliomas, Neuroblastoma in Adults, Hemangioma, and Ependymoma) are discussed.
Introduction to new technologies and their applications to tumor diagnosis, treatment, and therapy assessment are explained. Molecular pro fi ling of brain Preface tumors to select therapy in clinical trials of brain tumors is included. Several surgical treatments, including resection and radiosurgery, are discussed. The remaining volumes in this series will provide additional recent information on this and other aspects of CNS malignancies.
By bringing together a large number of experts (oncologists, neurosurgeons, physicians, research scientists, and pathologists) in various aspects of this medical fi eld, it is my hope that substantial progress will be made against this terrible disease. It would be dif fi cult for a single author to discuss effectively the complexity of diagnosis, therapy, and prognosis of any type of tumor in one volume. Another advantage of involving more than one author is to present different points of view on a speci fi c controversial aspect of the CNS cancer. I hope these goals will be ful fi lled in this and other volumes of this series. This volume was written by 68 contributors representing 17 countries. I am grateful to them for their promptness in accepting my suggestions. Their practical experience highlights their writings, which should build and further the endeavors of the reader in this important area of disease. I respect and appreciate the hard work and exceptional insight into the nature of cancer provided by these contributors. The contents of the volume are divided into nine parts: Lymphoma, Supratentorial Tumors, Glioneuronal Tumors, Gangliogliomas, Neuroblastoma in Adults, Astrocytoma and Ependymoma, Hemangiomas, Craniopharyngiomas, and Neurogenesis for the convenience of the reader.
It is my hope that the current volume will join the preceding volumes of the series for assisting in the more complete understanding of globally relevant cancer syndromes. There exists a tremendous, urgent demand by the public and the scienti fi c community to address to cancer diagnosis, treatment, cure, and hopefully prevention. In the light of existing cancer calamity, fi nancial funding by governments must give priority to eradicating this deadly malignancy over military superiority.
I am thankful to Dr. Dawood Farahi and Dr. Kristie Reilly for recognizing the importance of medical research and publishing through an institution of higher education. I am thankful to my students for their contribution to the prepartion of this volume. 
